Ngm Biopharmaceuticals Inc

NASDAQ:NGM  
20.41
-0.91 (-4.27%)
Products, Strategic Combinations

Ngm Amends Collaboration With Merck To Focus Primarily On Advancing Novel Medicines For Retinal And Cardiovascular And Metabolic Diseases

Published: 07/01/2021 11:14 GMT
Ngm Biopharmaceuticals Inc (NGM) - Ngm Amends Collaboration With Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (cvm) Diseases.
Ngm Biopharmaceuticals Inc - to Extend Their Ongoing Collaboration Through March 2024 But With a Narrower Scope.
Ngm Biopharmaceuticals - Under Terms of Amended Collaboration, Merck Will Provide About $120 Million in Research and Development Funding to Ngm Through March 2024.